RT Journal Article
SR Electronic
T1 RAY: CRISPR diagnostic for rapid and accurate detection of SARS-CoV2 variants on a paper strip
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.01.21250900
DO 10.1101/2021.02.01.21250900
A1 Kumar, Manoj
A1 Gulati, Sneha
A1 Ansari, Asgar Hussain
A1 Phutela, Rhythm
A1 Acharya, Sundaram
A1 Kathpalia, Poorti
A1 Kanakan, Akshay
A1 Maurya, Ranjeet
A1 Vasudevan, Janani Srinivasa
A1 Murali, Aparna
A1 Pandey, Rajesh
A1 Maiti, Souvik
A1 Chakraborty, Debojyoti
YR 2021
UL http://medrxiv.org/content/early/2021/02/03/2021.02.01.21250900.abstract
AB The COVID-19 pandemic originating in the Wuhan province of China in late 2019 has impacted global health, causing increased mortality among elderly patients and individuals with comorbid conditions. During the passage of the virus through affected populations, it has undergone mutations- some of which have recently been linked with increased viral load and prognostic complexities. Interestingly, several of these variants are point mutations that are difficult to diagnose using the gold standard quantitative real-time PCR (qPCR) method. This necessitates widespread sequencing which is expensive, has long turn-around times, and requires high viral load for calling mutations accurately. In this study, we show that the high specificity of Francisella novicida Cas9 (FnCas9) to point mismatches can be successfully adapted for the simultaneous detection of SARS-CoV2 infection as well as for detecting point mutations in the sequence of the virus obtained from patient samples. We report the detection of the mutation N501Y (earlier shown to be present in the British N501Y.V1, South African N501Y.V2, and Brazilian N501Y.V3 variants of SARS-CoV2) within an hour using paper strip chemistry. The results were corroborated using deep sequencing. Our design principle can be rapidly adapted for other mutations, highlighting the advantages of quick optimization and roll-out of CRISPR diagnostics (CRISPRDx) for disease surveillance even beyond COVID-19.Competing Interest StatementA patent application has been filed in relation to this work (0127NF2019). Funding StatementThis study was funded by CSIR Sickle Cell Anemia Mission (HCP0008), TATA Steel CSR (SSP2001) and a Lady Tata Young Investigator award (GAP0198) to D.C. The sequencing was funded by the CSIR (MLP-2005), Fondation Botnar (CLP-0031), Intel (CLP-0034) and IUSSTF (CLP-0033). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study was approved by the Ethics Committee, Institute of Genomics and Integrative Biology, New Delhi.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data presented in the manuscript will be made available upon reasonable request to the corresponding authors.